Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries.
CTCL
OS
TTNT
observational study
outcome
pcALCL
treatment
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
29 Dec 2021
29 Dec 2021
Historique:
received:
26
11
2021
revised:
22
12
2021
accepted:
23
12
2021
entrez:
11
1
2022
pubmed:
12
1
2022
medline:
12
1
2022
Statut:
epublish
Résumé
The treatment pattern of cutaneous T-cell lymphoma (CTCL) remains diverse and patient-tailored. The objective of this study was to describe the treatment patterns and outcomes in CTCL patients who were refractory or had relapsed (R/R) after a systemic therapy. A retrospective chart review study was conducted at 27 sites in France, Germany, Italy, Spain and the United Kingdom (UK) of patients who received a first course of systemic therapy and relapsed or were refractory. Data were collected longitudinally from diagnosis to first-, second- and third-line therapy. The study included 157 patients, with a median follow-up of 3.2 years. In total, 151 proceeded to second-line and 90 to third-line therapy. In the first line (
Identifiants
pubmed: 35008309
pii: cancers14010145
doi: 10.3390/cancers14010145
pmc: PMC8750476
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Lancet Oncol. 2018 Sep;19(9):1192-1204
pubmed: 30100375
Indian J Dermatol. 2017 Mar-Apr;62(2):142-145
pubmed: 28400633
Eur J Cancer. 2017 May;77:57-74
pubmed: 28365528
Ann Oncol. 2013 Oct;24 Suppl 6:vi149-54
pubmed: 23868906
Crit Rev Oncol Hematol. 2016 Mar;99:228-40
pubmed: 26811014
Cochrane Database Syst Rev. 2012 Jan 18;1:CD008908
pubmed: 22258991
Ann Oncol. 2017 Oct 1;28(10):2517-2525
pubmed: 28961843
Chin Clin Oncol. 2019 Feb;8(1):10
pubmed: 30818958
Dermatol Clin. 2015 Oct;33(4):643-54
pubmed: 26433839
Cancers (Basel). 2020 Oct 11;12(10):
pubmed: 33050643
Curr Oncol Rep. 2018 Mar 23;20(4):32
pubmed: 29572582
Lancet. 2017 Aug 5;390(10094):555-566
pubmed: 28600132
Drugs. 2010 Feb 12;70(3):273-86
pubmed: 20166766
Blood. 2005 May 15;105(10):3768-85
pubmed: 15692063
Blood. 2007 Sep 15;110(6):1713-22
pubmed: 17540844
Blood. 2009 May 21;113(21):5064-73
pubmed: 19279331
Blood. 2015 Jan 1;125(1):71-81
pubmed: 25336628
Ann Oncol. 2018 Oct 1;29(Suppl 4):iv30-iv40
pubmed: 29878045